Engineers build mini drug-producing biofactories in yeast

Researchers at the California Institute of Technology have developed a novel way to churn out large quantities of drugs, including antiplaque toothpaste additives, antibiotics, nicotine, and even morphine, using mini biofactories--in yeast.

A paper describing the research, now available online, will be featured as the cover article of the September issue of Nature Chemical Biology.

Christina D. Smolke, an assistant professor of chemical engineering at Caltech, along with graduate student Kristy Hawkins, genetically modified common baker's yeast (Saccharomyces cerevisiae) so that it contained the genes for several plant enzymes. The enzymes allow the yeast to produce a chemical called reticuline, which is a precursor for many different classes of benzylisoquinoline alkaloid (BIA) molecules. The BIA molecules are a large group of chemically intricate compounds, such as morphine, nicotine, and codeine, which are naturally produced by plants.

BIA molecules exhibit a wide variety of pharmacological activities, including antispasmodic effects, pain relief, and hair growth acceleration. Other BIAs have shown anticancer, antioxidant, antimalarial, and anti-HIV potential.

"There are estimated to be thousands of members in the BIA family, and having a source for obtaining large quantities of specific BIA molecules is critical to gaining access to the diverse functional activities provided by these molecules," says Smolke, whose lab focuses on using biology as a technology for the synthesis of new chemicals, materials, and products. However, the natural plant sources of BIAs accumulate only a small number of the molecules, usually "end products" like morphine and codeine that, while valuable, can't be turned into other compounds, thus limiting the availability of useful new products.

To their reticuline-producing yeast, Smolke and Hawkins added the genes for other enzymes, from both plants and humans, which allowed the yeast to efficiently generate large quantities of the precursors for sanguinarine, a toothpaste additive with antiplaque properties; berberine, an antibiotic; and morphine.

The researchers are now in the process of engineering their yeast so that they will turn these precursor molecules into the final, pharmacologically useful molecules. "But even the intermediate molecules that we are producing can exhibit important and valuable activities, and a related area of research will be to examine more closely the pharmacological activities of these metabolites and derivatives now that pure sources can be obtained," says Smolke, who estimates that her system could be used for the large-scale manufacture of BIA compounds in one to three years.

Smolke and Hawkins also plan to extend their research to the production of BIAs that don't normally exist in nature.

"If one thinks of these molecules as encoding functions that are of interest to us, the ability to produce nonnatural alkaloids will provide access to more diverse functions and activities. By expanding to nonnatural alkaloids, we can search for molecules that provide enhanced activities, new activities, and not be limited by the activities that have been selected for in nature," says Smolke.

"Our work has the potential to result in new therapeutic drugs for a broad range of diseases. This work also provides an exciting example of the increased complexity with which we are engineering biological systems to address global societal challenges," she says.

Source: California Institute of Technology

Related stories:

Nature Study Uncovers Structure of Key Protein Complex in Cells
Scientists at Memorial Sloan-Kettering Cancer Center (MSKCC) have uncovered the structure of a network of proteins that help regulate the life cycle of cells. Understanding the network's physical layout is an important step toward learning its precise function, and in finding ways to correct flaws in the system that could lead to cancer.
Timing is everything: First step in protein building revealed
Timing is everything, it seems, even in science. A team led by Johns Hopkins scientists has unraveled the first step in translating genetic information in order to build a protein, only to find that it's not one step but two.
In a series of experiments, the scientists found that when yeast's protein-building machinery recognizes the starting line for a gene's instructions, it first alters its structure and then releases a factor known as eIF1, a step necessary to let it continue reading the assembly instructions. Even though yeast are the most primitive relatives of humans, the protein-building machinery, or ribosomes, of each are quite similar.
Research on understanding DNA segregation earns top award for young life scientists
For his research of DNA segregation, assembly and regulation of bacterial actin-like proteins, and cytoskeleton, Ethan Clark Garner, a regional winner from North America, has been named the Grand Prize winner for the GE & Science Prize for Young Life Scientists. The competition, which includes a grand-prize award of $25,000, is supported by GE Healthcare and the journal Science, which is published by AAAS, the nonprofit science society.
Researchers develop technique to count messages made by single genes
In a study in the advance online edition of Nature Structural and Molecular Biology, researchers from Albert Einstein College of Medicine describe a technique for looking more precisely at a fundamental step of a cell's life – a gene, DNA, being read into a message, mRNA. The technique could provide a window into the process by which genes are switched on inappropriately, causing disease.
McGill researcher on a quest to cure disfiguring parasitic disease
Eating a meal in a restaurant is one of those trivial, everyday activities we take for granted in the developed world. For Canadian aid worker Louisette Pouliot, however, the simple act of grabbing a quick bite at an outdoor eatery in Ouagadougou, the capital of the African nation of Burkina Faso, had profound implications for her life and health.
Opening up the last part of the spectrum
(PhysOrg.com) -- New European research on the last, hidden part of the electromagnetic spectrum is producing new, safe and non-destructive tests for medicine, security and industrial quality control.
Scientists shed light on how DNA is unwound so that its code can be read
Researchers at The Scripps Research Institute have figured out how a macromolecular machine is able to unwind the long and twisted tangles of DNA within a cell's nucleus so that genetic information can be "read" and used to direct the synthesis of proteins, which have many specific functions in the body.
Scientists exploring new compounds to target muscular dystrophy
Scientists have identified a promising set of new compounds in the fight against muscular dystrophy. Using a drug-discovery technique in which molecules compete against each other for access to the target – the strand of toxic RNA that causes the most common form of muscular dystrophy in adults – a team at the University of Rochester Medical Center has identified several compounds that, in the laboratory, block the unwanted coupling of two molecules that is at the root of the disease.

News discussion:

General Science news